Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074746 · ClinicalTrials.gov registry record · Phase 1
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT04074746: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT04074746 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04074746, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of modified umbilical cord blood immune cells (natural killer \[NK\] cells) combined with the antibody AFM13 (AFM13-NK) and AFM13 alone in treating patients with CD30 positive Hodgkin lymphoma or non-Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as AFM13, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving AFM13 loaded with NK cells followed by AFM13 alone may kill more cancer cells and decrease cancer growth in patients with CD30 positive AFM13-NK Hodgkin and Non-Hodgkin lymphomas.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Fludarabine Phosphate
- BIOLOGICAL Genetically Engineered Lymphocyte Therapy
- BIOLOGICAL Anti-CD30/CD16A Monoclonal Antibody AFM13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-07-18 |
| Est. Completion | 2025-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04074746
The ClinicalTrials.gov registry entry for NCT04074746 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04074746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04074746 about?
NCT04074746 is a clinical study titled "Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas". This phase I/II trial studies the side effects and best dose of modified umbilical cord blood immune cells (natural killer \[NK\] cells) combined with the antibody AFM13 (AFM13-NK) and AFM13 alone in treating patients with CD30 positive Hodgkin lymphoma or non-Hodgkin lymphoma that has come back (re...
What is the current status of trial NCT04074746?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-07-18. Estimated completion is 2025-09-22.
What interventions are being tested in trial NCT04074746?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Fludarabine Phosphate (DRUG), Genetically Engineered Lymphocyte Therapy (BIOLOGICAL), Anti-CD30/CD16A Monoclonal Antibody AFM13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04074746?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.